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ABSTRACT
Introduction Gabapentin is an antiepileptic drug currently 
licensed to treat epilepsy and neuropathic pain but has 
been used off- label to treat acute postoperative pain. 
The GAP study will compare the effectiveness, cost- 
effectiveness and safety of gabapentin as an adjunct to 
standard multimodal analgesia versus placebo for the 
management of pain after major surgery.
Methods and analysis The GAP study is a multicentre, 
double- blind, randomised controlled trial in patients aged 
18 years and over, undergoing different types of major 
surgery (cardiac, thoracic or abdominal). Patients will be 
randomised in a 1:1 ratio to receive either gabapentin 
(600 mg just before surgery and 600 mg/day for 2 
days after surgery) or placebo in addition to usual pain 
management for each type of surgery. Patients will be 
followed up daily until hospital discharge and then at 4 
weeks and 4 months after surgery. The primary outcome 
is length of hospital stay following surgery. Secondary 
outcomes include pain, total opioid use, adverse health 
events, health related quality of life and costs.
Ethics and dissemination This study has been approved 
by the Research Ethics Committee . Findings will be 
shared with participating hospitals and disseminated to the 
academic community through peer- reviewed publications 
and presentation at national and international meetings. 
Patients will be informed of the results through patient 
organisations and participant newsletters.
Trial registration number ISRCTN63614165.
INTRODUCTION
About 4.7 million patients undergo surgery 
in the UK each year.1 Many patients expe-
rience significant pain after surgery and 
about 10% experience severe pain.2–5 Inad-
equate pain management increases the 
length of hospital stay6 and contributes to 
the development of chronic or persistent 
post- surgical pain,7 8 which impacts on quality 
of life.9 Current multimodal analgesic regi-
mens include paracetamol, non- steroidal 
anti- inflammatory drugs, regional analgesia 
(focused delivery of a local anaesthetic to a 
specific part of the body) and opioids.10
Opioids are key analgesic agents for 
managing moderate to severe pain. However, 
they have poor efficacy in movement- 
associated pain and have significant side- 
effects including confusion, nausea, vomiting, 
itching, constipation and respiratory depres-
sion. These side effects can increase the length 
Strengths and limitations of this study
 ► Pragmatic design integrated into standard care 
pathways.
 ► First trial to assess the impact of gabapentin on hos-
pital stay and quality of life.
 ► Implemented in three types of major surgery: cardi-
ac, thoracic and abdominal.
 ► Non- variable dose and limited duration of inter-
vention may reduce applicability (eg, frail/infirm 
patients and patients requiring analgesia for longer 
than 2 days).
 ► Only includes major body cavity surgery, which re-
duces applicability to major orthopaedic surgery.
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of hospital stay, delay overall recovery and reduce quality 
of life.9 Reliance on opioids after surgery also increases 
the risk of long- term use and opioid dependence.11 12 
Gabapentin is an antiepileptic drug currently licensed to 
treat epileptic convulsions and neuropathic pain. It is also 
commonly used off- label in the perioperative setting to 
reduce opioid use without compromising pain control. 
We conducted a survey of UK practice among consultant 
anaesthetists in the South West of England and members 
of the British Pain Society Acute Pain Special Interest 
Group. We found that 35/145 (23%) of anaesthetists 
prescribe gabapentin to their patients, with large vari-
ation in practice across the UK.13 Reducing opioid use 
after surgery to return patients to full health as quickly as 
possible, is one of the central tenets of enhanced recovery 
in the National Health Service (NHS).14 However, there 
is currently no robust evidence to recommend the inclu-
sion of gabapentin in enhanced recovery protocols.
There are over 130 randomised controlled trials 
(RCTs) that have investigated gabapentin versus placebo 
in different surgical populations. Most of these trials are 
small (<200 patients, median 80) and highly heteroge-
neous, both statistically and clinically. These RCTs have 
been included in 18 systematic reviews that aimed to 
assess the effectiveness of gabapentin versus placebo in 
the perioperative period; 11 of these in surgical popu-
lations.15–25 All reviews reached the same conclusions; 
that gabapentin reduced opioid consumption and post-
operative pain scores at 24 hours (p<0.001), but none 
has assessed the impact on quality of life. The most 
recent systematic review was published since this study 
started25 and assessed the impact of gabapentin on 
length of hospital stay in eight trials which provided very 
low to moderate quality evidence and found no statisti-
cally significant difference in the length of hospital stay 
between the gabapentin and control group.
The GAP study will compare the effectiveness, cost- 
effectiveness and safety of gabapentin versus placebo 
as an adjunct to standard multimodal analgesia for the 
management of pain after surgery. Specific objectives 
are to estimate: (i) the difference between groups in 
length of hospital stay following surgery; (ii) the differ-
ence between groups in total opioid use, pain, adverse 
events and health- related quality of life (HRQoL); and 
(iii) the cost effectiveness of gabapentin compared with 
usual care.
METHODS AND ANALYSIS
Trial design and population
The GAP study is a multicentre, parallel group, placebo- 
controlled, pragmatic double- blind RCT. Patients will 
be recruited from three surgical specialties (cardiac, 
thoracic and abdominal) across several secondary care 
NHS centres (figure 1). A principal investigator will be 
appointed in each centre and clinical leads will be identi-
fied for each specialty within each centre.
GAP includes two phases: (i) phase I (12 months) 
involves study set- up and recruitment from two NHS 
secondary centres (University Hospitals Bristol and 
Weston NHS Foundation Trust and University Hospitals 
Southampton NHS Foundation Trust) with integrated 
monitoring of the recruitment process to maximise 
recruitment and adherence with the study medication; 
Figure 1 Trial schema.
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(ii) phase II (18 months) continued recruitment using 
the optimum methods established in phase I, opening 
additional centres (if required). Progression from phase 
I to phase II is contingent on demonstrating that after 9 
months of recruitment in phase I, sufficient numbers of 
patients referred for surgery are eligible for the trial and 
can be enrolled to complete the main trial. Specifically:
1. At least 60% of patients undergoing surgery are con-
sidered eligible.
2. At least 50% of eligible patients consent to randomisa-
tion by 6 months of recruitment at each centre.
Eligibility criteria
Patients will be eligible for the study if all the following 
apply:
1. Over 18 years of age.
2. Undergoing non- emergency surgery: (i) cardiac (sur-
gery on the heart and great vessels performed via 
midline sternotomy); (ii) thoracic (open or minimal 
access surgery on the lungs and surrounding tissues); 
(iii) abdominal (open or minimal access surgery with-
in the abdominal cavity).
3. Expected to stay in hospital at least until day 2 after 
surgery (day 0 is day of surgery).
4. Expected to be able to swallow during the time of the 
study intervention.
Patients will be excluded from the study if any of the 
following apply:
1. Taking antiepileptic medication(s).
2. Gabapentin allergy.
3. Already taking gabapentin or gabapentanoids.
4. Galactose intolerance, Lapp lactase deficiency or 
glucose- galactose malabsorption.
5. Planned epidural analgesia.
6. Intended use of any gabapentanoids in the periop-
erative analgesic protocol other than the study 
medication (this includes but is not restricted to: pre-
gabalin, enacarbil gabapentin, 4- methylpregabalin 
and phenibut).
7. Known renal impairment (estimated glomerular fil-
tration rate <30 mL/min/1.732).
8. Weight <50 kg.
9. Inability to provide written informed consent.
10. Unwilling to participate in follow- up.
11. Prisoners.
12. Enrolled in another clinical trial and: (i) the patient 
is currently taking an investigational medicinal prod-
uct as part of the other trial; or (ii) coenrolment is 
not permitted by the other trial; or (iii) coenrolment 
would be burdensome for the patient.
Patient approach and consent
Potential patients will be identified from clinic and 
planned operating lists and those eligible to participate 
will receive a patient information leaflet (PIL). Most 
patients will have at least 24 hours to consider partici-
pation. However, it is important to include urgent, non- 
emergency patients who may have less than 24 hours to 
consider the study, to maximise the applicability of the 
findings. In these circumstances, patients will only be 
enrolled if they confirm that they have had enough time 
to consider their participation.
Prior to surgery, patients will be seen by a member of 
the local research team who will answer any questions, 
confirm eligibility and receive written informed consent 
if the patient decides to participate. Details of all patients 
approached and reasons for non- participation (eg, inel-
igibility or patient refusal) will be documented. The 
patients’ general practitioners will be informed of their 
enrolment in the study. Participants can withdraw at any 
time and will be treated according to standard hospital 
procedures. If a participant decides that they no longer 
wish to take part in study procedures, data collection for 
those procedures will cease. These participants will be 
asked whether they are still willing to participate in the 
study follow- up, if applicable.
Interventions
The study intervention is gabapentin 600 mg given preop-
eratively and 600 mg/day (300 mg in the morning and 
300 mg in the evening) given postoperatively for 2 days 
when clinically able to swallow following extubation (if 
applicable). The control is a placebo, taken at the same 
time- points as the active tablet. Both gabapentin and 
placebo will be administered within local multimodal 
analgesic regimens. The study medication (gabapentin/
placebo) is manufactured, packaged and labelled in 
accordance with Good Manufacturing Practice and is 
stored at room temperature, below 25°C.
Use of any gabapentanoids other than the study medi-
cation during the study intervention period is prohibited. 
If the preoperative dose is administered and surgery is 
postponed by more than 12 hours, a second preoperative 
dose of study medication will be given before the resched-
uled surgery. If a postoperative dose of study medication 
is missed by less than 6 hours, patients should be given the 
missed dose and continue to the next scheduled dose as 
per the protocol. If a dose of study medication is missed 
by 6 hours or more, patients should continue to the next 
scheduled dose and should not be given the missed dose. 
For patients intubated for longer than 48 hours after the 
end of surgery, no postoperative study medication should 
be administered. All other aspects of patient’s care will be 
performed according to local practice.
Randomisation
Randomisation will be performed after eligibility has 
been confirmed, using a secure internet- based randomi-
sation system to ensure allocation concealment. Patients 
will be allocated in a 1:1 ratio to either gabapentin or 
placebo. A computer- generated allocation sequence will 
be prepared by an the unblinded study statistician. The 
random allocation will be blocked with blocks of varying 
size and stratified by centre and specialty, so that each 
specialty at each centre will have approximately equal 
numbers of patients allocated to placebo and gabapentin. 
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To maintain blinding, the randomisation system will only 
reveal a unique pack number, which identifies the study 
medication to be given.
Blinding
Patients, their clinical care team (ie, surgeon, anaesthe-
tist and those responsible for their postoperative care) 
and the research nurses will not be informed of the allo-
cation. Patients will be made aware before entering the 
study that they will not be told which treatment they will 
receive. Doctors will prescribe ‘study medication’ rather 
than specifically gabapentin or placebo. The unique 
pack number provided by the randomisation system will 
provide the medication as specified by the predetermined 
randomisation list. The allocations will only be known by 
pharmacy and the unblinded study statistician and will 
not be disclosed to other members of the research team. 
The treatment allocation will only be unblinded if clini-
cally indicated; for example, in the event of a suspected 
serious adverse reaction to the study medication, the 
management of which might be altered by knowledge of 
the allocation.
The study medication is over- encapsulated to maintain 
blinding. The capsules for active drug and placebo will 
look identical and do not have a particularly strong or 
unusual smell or taste, so we do not anticipate unblinding 
will occur due to the characteristics of the medication. 
Gabapentin may induce side- effects that may inadver-
tently unblind patients and/or clinical teams. However, 
given that the side effects of gabapentin (eg, drowsiness, 
dizziness and difficulty concentrating) are similar to 
those of opioids, and that patients/clinical care teams 
are likely to view side effects as resulting from their whole 
surgical and postoperative experience, it is unlikely that 
any patient/clinician will definitively be able to attribute a 
specific side effect to gabapentin. The PIL and the process 
of informed consent explain the uncertainty around the 
potential beneficial effects of gabapentin over a placebo. 
Therefore, in the event of inadvertent unblinding, 
patients should not have a strong expectation that one or 
other method should lead to a more favourable outcome. 
The success of blinding will be assessed using the Bang 
Blinding Index (BBI).26
Outcomes
The primary outcome is length of hospital stay, from start 
of surgery to hospital discharge. The secondary outcomes 
include:
1. Acute postoperative pain assessed using the numerical 
rating scale completed at rest and on movement (on 
mobilisation, deep breathing or coughing) at 1 hour, 
4 hours, 12 hours postsurgery and then two times per 
day until discharge.
2. Opioid consumption in the period from: (i) surgery 
until hospital discharge; (ii) discharge until 4 months.
3. Adverse health events in the period from: (i) randomi-
sation to discharge; (ii) discharge until 4 months.
4. HRQoL measured using the EuroQol 5 dimension five 
level questionnaire (EQ- 5D 5L) and Short- form (SF) 
12 completed at baseline, 4 weeks and 4 months.
5. Resource use to 4 months (measured during the hospi-
tal stay, at 4 weeks and 4 months).
6. Chronic pain measured using the brief pain inventory 
at baseline, at 4 weeks and 4 months.
Data collection
Screening data will be collected before consent to estab-
lish patient eligibility. The schedule of data collection 
outlined in table 1 will take place after consent has been 
received. Data will be collected onto paper data collection 
forms, entered onto a bespoke study database and stored 
on a secure server. Patient reported questionnaire data is 
also stored on the study database. Data for the primary 
outcome and most secondary outcomes will be collected 
during the hospital stay. Patients will be followed up at 
approximately 4 weeks and at 4 months for information 
on pain, adverse events, resource use and quality of life.
The study will end for a participant after they have 
completed follow- up at 4 months postsurgery. The end of 
the study as a whole will be after all study participants have 
completed follow- up, all data queries have been resolved, 
the database locked and the analysis completed.
Sample size
A total of 1500 participants will be randomised to either 
gabapentin or placebo. The target difference in length 
of hospital stay was chosen to reflect the effect size that 
would persuade clinicians to change practice and is 
expressed in terms of the increase in the proportion 
of patients discharged at the current median time to 
discharge (5 days for cardiac and abdominal surgery, 3 
days for thoracic surgery). This sample size will have 90% 
power to detect a difference of 12.5% in each specialty 
(ie, 50% vs 62.5%) if the number of participants per 
surgical stratum exceeds 376 and 80% power to detect a 
difference of 10% in each specialty (ie, 50% vs 60%) if the 
number of participants per surgical stratum exceeds 430, 
assuming: 5% two- sided type I error rate, 5% censoring 
and constant HR.
Statistical analyses
The analyses will be conducted according to intention- 
to- treat and follow Consolidated Standards of Reporting 
Trials reporting guidelines. Randomised participants who 
fail to complete the course of treatment will be included 
in the primary analysis. All models will compare the treat-
ment groups, will be adjusted for centre and will include 
a treatment by specialty interaction so the treatment 
effect in each surgical specialty can be quantified and 
compared.
The primary outcome analysis of whether there is a 
difference between gabapentin and placebo with respect 
to length of hospital stay will use Cox proportional hazards 
regression. Those participants who die before discharge 
will be censored at the longest recorded length of stay 
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for that specialty, as this is computationally equivalent to 
competing risk methodology in this setting.
Opioid consumption, pain scores and HRQoL 
outcomes will all be analysed using mixed regression 
models, adjusted for baseline measures where appro-
priate. Changes in treatment effect with time will be 
assessed by adding a treatment by time interaction to the 
model and comparing models using a likelihood ratio 
test. Deaths will be accounted for by modelling HRQoL 
and survival jointly. Model fit will be assessed and alter-
native models and/or transformations (eg, to induce 
normality) will be explored where appropriate. Safety will 
be assessed by summarising the number and proportion 
of participants reporting serious and non- serious adverse 
events and will be reported to the Data Monitoring and 
Safety Committee (DMSC) on a regular basis.
The health economic evaluation will compare the costs 
and effects of gabapentin compared with placebo for the 
management of pain after major surgery. The within- 
trial cost- effectiveness analysis will be undertaken from 
an NHS and personal social services perspective, with a 
4- month time horizon from the day of surgery. Effects will 
be measured using quality- adjusted life years (QALYs), 
estimated using EQ- 5D 5L.27 28 Costs will include medica-
tion costs and those related to inpatient stay. Established 
guidelines as set out by the National Institute for Health 
and Care Excellence29 will be followed for the economic 
evaluation. The incremental cost- effectiveness ratio will 
be calculated from the average costs and QALYs in each 
trial group to produce an incremental cost per QALY of 
gabapentin compared with placebo.30
Exploratory subgroup analyses are planned to explore 
the primary and secondary outcomes in terms of type of 
surgery (open/minimal access).
Data handling, storage and sharing
Data will be stored in a bespoke database hosted on the 
NHS network. Access to the database will be via a secure 
password- protected web- interface. All study documen-
tation will be retained in a secure location during the 
study and for 15 years after the end of the study, when 
all patient identifiable paper records will be destroyed by 
confidential means. Medical records documenting study 
related information will be identified by a label bearing 
the name and duration of the study. In compliance with 
the Medical Research Council Policy on Data Sharing, 
relevant ‘meta’-data about the study and the full dataset, 
but without any participant identifiers other than the 
unique participant identifier, will be held indefinitely on 
a University of Bristol server. A secure electronic ‘key’ 
with a unique participant identifier, and key personal 
identifiers will also be held indefinitely, but in a separate 
file and in a physically different location (NHS hospital 
server). These will be retained because of the potential 
for the raw data to be used subsequently for secondary 
research.
Risk of bias
The following key features have been incorporated into 
the study to minimise the risk of bias:
1. Selection/allocation bias arising from the randomi-
sation process will be prevented by using computer- 
generated concealed randomisation. Allocation lists 
Table 1 Schedule of data collection












Sociodemographic details ✓           
Comorbidities ✓           
Routine clinical measures ✓     ✓   
Resource use schedule       ✓ ✓ ✓
SF-12 ✓       ✓ ✓
EQ- 5D 5L ✓       ✓ ✓
BPI ✓       ✓ ✓
NRS pain score ✓*   ✓* ✓   
Study medication ✓ ✓†     
Opioid use ✓ ✓ ✓ ✓ ✓ ✓
Adverse events     ✓ ✓   
Serious adverse events     ✓ ✓ ✓ ✓
*Routinely collected NRS pain scores as close as possible to the following time points may be used: prerandomisation, 1 hour, 4 hours, 
12 hours postsurgery and two times per day postsurgery until discharge. NRS pain assessments will not be possible in intubated patients.
†Study medication given morning and evening for 2 days following extubation (where applicable).
BPI, brief pain inventory; NRS, numerical rating scale.
 on D
ecem









pen: first published as 10.1136/bm






6 Baos S, et al. BMJ Open 2020;10:e041176. doi:10.1136/bmjopen-2020-041176
Open access 
prepared by an unblinded statistician will be strati-
fied by centre and specialty to minimise confound-
ing. Participants will be randomised after eligibility is 
confirmed.
2. Performance bias arising from deviations from intend-
ed interventions will be minimised by blinding all par-
ticipants, clinicians and other hospital staff caring for 
participants and members of the research team (apart 
from the study unblinded statistician) to participants’ 
allocation. The success of blinding will be assessed by 
asking participants and research nurses responsible 
for participant care and data collection to complete 
the BBI at the point of discharge from hospital. Par-
ticipants will complete the BBI again 4 months after 
surgery.26 Performance bias will also be minimised by 
administering the study medication according to stan-
dard protocols and by predefining all other study pro-
cedures and applying these to all participants in the 
same way. Adherence to all aspects of the protocol will 
be monitored.
3. Detection bias arising from differences in how the out-
come is measured will be minimised by blinding all in-
dividuals assessing outcomes, assessing the success of 
blinding and providing clear unambiguous definitions 
for each outcome measure.
4. Attrition bias arising from missing outcome data will 
be minimised by (i) maintaining contact with partic-
ipants throughout the duration of the study to maxi-
mise the proportion of participants for whom all out-
come data are available, (ii) implementing measures 
to promote adherence (eg, training for staff admin-
istering the intervention, posters to remind the care 
team of patient study participation) and (iii) docu-
menting non- adherence to the allocated treatment. 
The data will also be analysed by intention- to- treat. In 
estimating the target sample size, loss to follow- up has 
not been allowed for as the primary outcome is time to 
hospital discharge and the follow- up period is short (4 
months). However, attention will be paid to keeping in 
touch with participants and maximising retention up 
to 4 months.
5. Reporting bias will be minimised by having prespeci-
fied outcomes and a prespecified analysis plan.
Patient and public involvement
Patient and public involvement (PPI) input was sought 
at the study design phase from relevant surgical PPI 
groups: the National Institute of Health Reasearch Bristol 
Biomedical Research Centre (Nutrition) colorectal PPI 
group, the Royal Brompton Hospital Cancer Consortia 
PPI group and patients who underwent cardiac surgery 
at the Bristol Heart Institute. GAP also includes a patient 
co- applicant. All PPI groups and the patient co- applicant 
unanimously agreed that the study was important and 
welcomed treatments that might reduce the amount of 
opioid drugs patients receive, and their associated side 
effects, after surgery. PPI groups provided feedback on 
the study intervention and outcome data collection (eg, 
pain scores and questionnaires), which informed the 
study design.
PPI engagement will continue during study imple-
mentation, including writing and designing participant- 
facing documents and outlining the participant follow- up 
schedule. The GAP study Trial Steering Committee (TSC) 
includes two public members who regularly review study 
progress.
PPI groups will continue to help with all aspects of 
the study, including preparing lay results summaries for 
dissemination to participants and other patient groups in 
order to maximise public awareness of the findings.
Ethics and dissemination
The study received Research Ethics Committee (REC) 
approval from Yorkshire and the Humber—Sheffield 
REC in November 2017, Medicines and Healthcare Regu-
latory Agency approval in December 2017 and Health 
Research Authority (HRA) approval in January 2018.
The study is sponsored by University Hospitals Bristol 
and Weston NHS Foundation Trust ( www. uhbristol. nhs. 
uk/ research- innovation/) and is coordinated by the 
Bristol Trials Centre, Clinical Trials and Evaluation Unit, 
(BTC (CTEU)), a UK Clinical Research Collaboration 
registered Clinical Trials Unit (reference 11). The TSC 
is made up of representatives from the GAP study team 
and independent members approved by the funder. The 
DMSC consists of an independent medical statistician and 
medical experts in this field approved by the funder. The 
TSC and DMSC meet as frequently as they feel is neces-
sary, usually at least once a year.
Changes to the protocol since REC/HRA approval
Following REC and HRA approval several changes have 
been made to the study protocol, as follows: (i) safety 
reporting requirement updates; (ii) reference safety drug 
information updates; (iii) clarifications about the level of 
care provided to study participants; (iv) clarifications that 
patients must be expected to be able to swallow during 
the time of the study intervention to be eligible; (v) clar-
ification that the first postoperative dose should only be 
administered if patients are clinically able to swallow; (vi) 
study medication packs contain six capsules instead of 
eight (to minimise the chance of participants receiving 
more study medication doses than intended); (vii) 
permitting eligibility and prescription sign off by non- 
doctor clinicians (eg, nurse practitioners); (viii) provision 
of optional patient diaries; (ix) opening to recruitment 
from more centres; and (x) study team contact detail 
updates. Protocol version 8.0 (dated 03 December 2019) 
is currently in use.
Dissemination of findings
Findings will be disseminated to participating hospitals 
and to the academic community through peer- reviewed 
publications and presentation at national and interna-
tional meetings. Findings will also be shared with study 
participants who express a wish to receive study results 
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through patient organisations, leaflets and newsletters. 
Study updates are regularly provided to the study team, 
participants and members of the public though emails, 
newsletters, magazine articles and social media.
DISCUSSION
The study design, involving three surgical specialties, 
was chosen because it is efficient and maximises the 
value of the research for the NHS. The inclusion of 
different surgical specialties reflects current clinical prac-
tice (gabapentin is prescribed to patients undergoing 
different surgical procedures) and should make the trial 
results generalisable in the NHS. The study opened to 
recruitment on 12 April 2018 and is currently recruiting 
in six centres. To date, 853 patients have been recruited 
(469 cardiac, 221 thoracic, 163 abdominal). The progres-
sion criteria were met and approvals to progress to phase 
II were received on 04 March 2019. GAP has proven more 
difficult to deliver than anticipated for a study which was 
perceived to have a straightforward intervention. Patient 
eligibility and patient willingness to participate have not 
been a limit to recruitment. Some of the challenges of 
delivering the study include (i) higher than expected 
training requirements to integrate administration of study 
medication into routine clinical practice in all specialties 
at participating centres, (ii) difficulties of using multiple 
clinical prescribing systems (electronic and paper) which 
are not linked and require multiple manual updates for 
a single in- hospital patient stay, (iii) higher than antici-
pated research team resource required to meet regula-
tory requirements (eg, obtaining clinician eligibility sign 
off, often during unsocial hours, or additional require-
ments following the reclassification of gabapentin as a 
schedule three controlled drug in April 2019); and (iv) 
regulatory structures that do not permit the study to have 
a designated principal investigator for each specialty in a 
centre. This is particularly challenging when patients are 
under the care of different clinical teams that are admin-
istratively and geographically separate. Further details 
about the challenges of delivering the GAP study in an 
NHS setting will be reported elsewhere. This study high-
lights that while the design is methodologically attractive, 
the current regulatory structures and NHS systems make 
implementation suboptimal.
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